An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Doxercalciferol (Primary) ; Calcitriol
- Indications Hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Planned End Date changed from 1 Mar 2020 to 2 Apr 2020.
- 09 Feb 2017 Planned primary completion date changed from 1 Mar 2020 to 27 Dec 2019.